USE OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY FOR NEOADJUVANT TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER

摘要

The present invention relates to the use of Pertuzumab in combination with Trastuzumab and carboplatin-based chemotherapy comprising Docetaxel and Carboplatin for the neoadjuvant treatment of early-stage HER2-positive breast cancer in a patient, wherein the early-stage HER2-positive breast cancer does not spread beyond the breast or the axillary lymph nodes, and wherein carboplatin-based chemotherapy comprisesg Docetaxel and Carboplatin.